Unconjugated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Monomer, MALS verified)

Produktübersicht

• Artikelname: Unconjugated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Monomer, MALS verified)
• Artikelnummer: ABS-HL1-H82EA-25UG
• Hersteller Artikelnummer: HL1-H82Ea-25ug
• Alternativnummer: ABS-HL1-H82EA-25UG
• Hersteller: AcroBiosystems
• Wirt: Human
• Kategorie: Proteine/Peptide
• Spezies Reaktivität: Human
• Konjugation: Unconjugated

Produktbeschreibung

NYESO1, which is also wellknown as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancertestis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLAA2 restricted NYESO1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatmentrefractory melanoma patients. The Human HLAA*0201 NYESO1 complex protein is a complex of HLAA*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NYESO1. - Proteine/Peptide

Produkteigenschaften

• Molekulargewicht: 36.3 kDa and 11.7 kDa
• Tag: C-10*His & C-Avi
• NCBI: 59606
• Puffer: PBS, pH7.4
• Reinheit: 90%
• Formulierung: Powder
• Target-Kategorie: HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQC)

Bilder

Immobilized Unconjugated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82Ea) at 5 µg/mL (100 µL/well) can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.2-16 ng/mL (QC tested).

Immobilized Anti-NY-ESO-1 Antibody, Human IgG1 at 1 µg/mL (100 µL/well) can bind Unconjugated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82Ea) with a linear range of 0.008-0.125 µg/mL (Routinely tested).

Unconjugated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.